Total net revenue decreased by 4.9% to $76.0 million in the fourth quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased by 3.9% to $70.3 million in the fourth quarter of 2019, compared to the same quarter in 2018. BURLINGAME, Calif. --(BUSINESS WIRE)--Feb.

MARINA DEL REY , Calif. and BRISBANE, Calif. , Jan. 28, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and Innoviva, Inc.

Total net revenue increased by 7% to $65.8 million in the third quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 15% to $57.6 million in the third quarter of 2019, compared to the same quarter in 2018. BRISBANE, Calif. --(BUSINESS WIRE)--Oct.

  LONDON --(BUSINESS WIRE)--Oct. 2, 2019-- GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration ( FDA ) seeking an additional indication for the use of once-daily, single-inhaler triple

Total net revenue decreased by 4% to $64.1 million in the second quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased slightly to $56.5 million in the second quarter of 2019, compared to the same quarter in 2018. BRISBANE, Calif. --(BUSINESS WIRE)--Jul.

LONDON --(BUSINESS WIRE)--May 2, 2019-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol:

Total net revenue increased by 5% to $55.2 million in the first quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 60% to $48.5 million in the first quarter of 2019, compared to the same quarter in 2018. BRISBANE, Calif.

Total net revenue rose 15% to $79.9 million in the fourth quarter of 2018 compared with the fourth quarter of 2017. 1 Income before income taxes increased 25% from the fourth quarter of 2017 to $73.1 million . BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 6, 2019-- Innoviva, Inc.

First single inhaler triple therapy to be specifically indicated for COPD patients not adequately treated with dual bronchodilation LONDON --(BUSINESS WIRE)--Nov. 9, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has

Total net revenue rose 26.8% to $61.7 million compared with the third quarter of 2017. Net income attributable to Innoviva stockholders increased 98.1% from the third quarter of 2017 to $47.1 million , or $0.43 per diluted share. The Company made a partial repayment of $110.0 million on its Term B